

Title (en)
COMBINATION OF ANTI-CD303 AND ANTI-HER2 ANTIBODIES

Title (de)
KOMBINATION AUS ANTI-CD303- UND ANTI-HER2-ANTIKÖRPERN

Title (fr)
COMBINAISON D'ANTICORPS ANTI-CD303 ET ANTI-HER2

Publication
EP 3555133 A1 20191023 (FR)

Application
EP 17826467 A 20171215

Priority
• FR 1662603 A 20161216
• EP 2017083157 W 20171215

Abstract (en)
[origin: WO2018109210A1] The present invention relates to a pharmaceutical composition comprising, in a pharmaceutically acceptable carrier: a) at least one anti-CD303 antibody; and b) at least one anti-HER2 antibody. The invention also relates to the combination of the two aforementioned antibodies a) and b) to form combination products to be used simultaneously, separately or spread out over a period of time, for the prevention or treatment of HER2-positive cancer.

IPC 8 full level
A61P 35/00 (2006.01); **C07K 16/28** (2006.01); **C07K 16/32** (2006.01)

CPC (source: EP US)
A61P 35/00 (2017.12 - EP US); **C07K 16/2851** (2013.01 - EP US); **C07K 16/32** (2013.01 - EP US); **A61K 2039/507** (2013.01 - EP US); **C07K 2317/12** (2013.01 - EP US); **C07K 2317/20** (2013.01 - US); **C07K 2317/21** (2013.01 - US); **C07K 2317/24** (2013.01 - US); **C07K 2317/41** (2013.01 - EP US); **C07K 2317/565** (2013.01 - US)

Citation (search report)
See references of WO 2018109210A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2018109210 A1 20180621; EP 3555133 A1 20191023; FR 3060395 A1 20180622; FR 3060395 B1 20190524; US 2019330369 A1 20191031

DOCDB simple family (application)
EP 2017083157 W 20171215; EP 17826467 A 20171215; FR 1662603 A 20161216; US 201716470032 A 20171215